A slowly growing malignant neoplasm derived from cartilage cells, occurring most frequently in pelvic bones or near the ends of long bones, in middle-aged and old people. Most chondrosarcomas arise de novo, but some may develop in a preexisting benign cartilaginous lesion or in patients with ENCHONDROMATOSIS. (Stedman, 25th ed)
A rare aggressive variant of chondrosarcoma, characterized by a biphasic histologic pattern of small compact cells intermixed with islands of cartilaginous matrix. Mesenchymal chondrosarcomas have a predilection for flat bones; long tubular bones are rarely affected. They tend to occur in the younger age group and are highly metastatic. (DeVita Jr et al., Cancer: Principles & Practice of Oncology, 3d ed, p1456)
A benign neoplasm derived from mesodermal cells that form cartilage. It may remain within the substance of a cartilage or bone (true chondroma or enchondroma) or may develop on the surface of a cartilage (ecchondroma or ecchondrosis). (Dorland, 27th ed; Stedman, 25th ed)
Tumors or cancer located in bone tissue or specific BONES.
Benign growths of cartilage in the metaphyses of several bones.
A malignant tumor arising from the embryonic remains of the notochord. It is also called chordocarcinoma, chordoepithelioma, and notochordoma. (Dorland, 27th ed)
A sarcoma, usually a liposarcoma or malignant fibrous histiocytoma, with an abundant component of myxoid tissue resembling primitive mesenchyme containing connective tissue mucin. (Stedman, 25th ed)
A non-vascular form of connective tissue composed of CHONDROCYTES embedded in a matrix that includes CHONDROITIN SULFATE and various types of FIBRILLAR COLLAGEN. There are three major types: HYALINE CARTILAGE; FIBROCARTILAGE; and ELASTIC CARTILAGE.
Neoplasms of the base of the skull specifically, differentiated from neoplasms of unspecified sites or bones of the skull (SKULL NEOPLASMS).
Hereditary disorder transmitted by an autosomal dominant gene and characterized by multiple exostoses (multiple osteochondromas) near the ends of long bones. The genetic abnormality results in a defect in the osteoclastic activity at the metaphyseal ends of the bone during the remodeling process in childhood or early adolescence. The metaphyses develop benign, bony outgrowths often capped by cartilage. A small number undergo neoplastic transformation.
Neoplasms developing from some structure of the connective and subcutaneous tissue. The concept does not refer to neoplasms located in connective or soft tissue.
A sarcoma originating in bone-forming cells, affecting the ends of long bones. It is the most common and most malignant of sarcomas of the bones, and occurs chiefly among 10- to 25-year-old youths. (From Stedman, 25th ed)
A set of twelve curved bones which connect to the vertebral column posteriorly, and terminate anteriorly as costal cartilage. Together, they form a protective cage around the internal thoracic organs.
Bones that constitute each half of the pelvic girdle in VERTEBRATES, formed by fusion of the ILIUM; ISCHIUM; and PUBIC BONE.
Enzymes which catalyze the elimination of glucuronate residues from chondroitin A,B, and C or which catalyze the hydrolysis of sulfate groups of the 2-acetamido-2-deoxy-D-galactose 6-sulfate units of chondroitin sulfate. EC 4.2.2.-.
Rare, benign, chronic, progressive metaplasia in which cartilage is formed in the synovial membranes of joints, tendon sheaths, or bursae. Some of the metaplastic foci can become detached producing loose bodies. When the loose bodies undergo secondary calcification, the condition is called synovial osteochondromatosis.
Glycoproteins which have a very high polysaccharide content.
A cartilage-capped benign tumor that often appears as a stalk on the surface of bone. It is probably a developmental malformation rather than a true neoplasm and is usually found in the metaphysis of the distal femur, proximal tibia, or proximal humerus. Osteochondroma is the most common of benign bone tumors.
Cancer or tumors of the MAXILLA or upper jaw.

Analysis of acute vascular damage after photodynamic therapy using benzoporphyrin derivative (BPD). (1/542)

Benzoporphyrin derivative monoacid ring A (BPD-MA, verteporfin) is currently under investigation as a photosensitizer for photodynamic therapy (PDT). Since BPD exhibits rapid pharmacokinetics in plasma and tissues, we assessed damage to tumour and muscle microvasculature when light treatment for PDT was given at short times after injection of photosensitizer. Groups of rats with chondrosarcoma were given 2 mg kg(-1) of BPD intravenously 5 min to 180 min before light treatment of 150 J cm(-2) 690 nm. Vascular response was monitored using intravital microscopy and tumour cure was monitored by following regrowth over 42 days. For treatment at 5 or 30 min after BPD injection, blood flow stasis was limited to tumour microvasculature with lesser response in the surrounding normal microvasculature, indicating selective targeting for damage. No acute changes were observed in vessels when light was given 180 min after BPD injection. Tumour regression after light treatment occurred in all animals given PDT with BPD. Long-term tumour regression was greater in animals treated 5 min after BPD injection and least in animals given treatment 180 min after drug injection. The correlation between the timing for vascular damage and cure implies that blood flow stasis plays a significant role in PDT-induced tumour destruction.  (+info)

The EWS/TEC fusion protein encoded by the t(9;22) chromosomal translocation in human chondrosarcomas is a highly potent transcriptional activator. (2/542)

The EWS/TEC gene fusion generated by the t(9;22) chromosomal translocation found in extraskeletal myxoid chondrosarcomas encodes a fusion protein containing the amino-terminal domain of the EWS protein fused to the whole coding sequence of the orphan nuclear receptor TEC. We have compared the DNA-binding and transcriptional activation properties of various TEC isoforms and the corresponding EWS/TEC fusion proteins. Band-shift experiments show that the full-length TEC receptor can efficiently bind the NGFI-B Response Element (NBRE), whereas an isoform lacking the entire carboxyl-terminal domain of the receptor binds much less efficiently the NBRE. Addition of the amino-terminal domain of EWS to either isoforms does not alter significantly their DNA-binding properties to the NBRE. Co-transfection experiments of COS cells and human chondrocytes indicate that whereas TEC moderately activates transcription from a NBRE-containing promoter, the corresponding EWS/TEC fusion protein is a highly potent transcriptional activator of the same promoter, being approximately 270-fold more active than the native receptor. EWS/TEC may thus exert its oncogenic potential in chrondrosarcomas by activating the transcription of target genes involved in cell proliferation.  (+info)

Sulphation heterogeneity in the trisaccharide (GalNAcSbeta1, 4GlcAbeta1,3GalNAcS) isolated from the non-reducing terminal of human aggrecan chondroitin sulphate. (3/542)

We report here the isolation and sulphation isomer analyses of trisaccharides GalNAcS(beta1,4)GlcA(beta1,3)GalNAcS (in which S indicates sulphate) derived from the non-reducing termini of aggrecan chondroitin sulphate. Rat chondrosarcoma and human aggrecans were digested for 1 h at 37 degrees C with 30 micro-units of endo-chondroitinase ABC per microgram of chondroitin sulphate, and trisaccharides were isolated from the digests by ToyoPearl HW40S gel-filtration chromatography. Four trisaccharide species were identified; their sulphation isomer compositions, as determined by digestion with chondroitinase ACII and fluorescence-based ion-exchange HPLC, were GalNAc4Sbeta1,4GlcAbeta1,3GalNAc4S, GalNAc4Sbeta1,4GlcAbeta1,3GalNAc6S, GalNAc4,6Sbeta1,4GlcAbeta1, 3GalNAc4S and GalNAc4,6Sbeta1,4GlcAbeta1,3GalNAc6S. The abundances of such sequences in chondroitin sulphate on aggrecan from normal (foetal to 72 years of age) and from osteoarthritic human knee cartilages were also established. The results showed that non-reducing terminal GalNAc4S or GalNAc4,6S can be linked to either a 4-sulphated or a 6-sulphated disaccharide, suggesting that the sulphation of the last disaccharide might not have a direct effect on the specificity of chondroitin sulphate terminal GalNAc sulphotransferases. Furthermore, for each aggrecan preparation examined, the 4S-to-6S ratio of all chain interior disaccharides was equivalent to that in the last repeating disaccharides at the non-reducing terminus, suggesting that neither chondroitin 4-sulphotransferase nor chondroitin 6-sulphotransferase shows preferential activity near the chain terminus.  (+info)

EXT-mutation analysis and loss of heterozygosity in sporadic and hereditary osteochondromas and secondary chondrosarcomas. (4/542)

Osteochondromas occur as sporadic solitary lesions or as multiple lesions, characterizing the hereditary multiple exostoses syndrome (EXT). Approximately 15% of all chondrosarcomas arise within the cartilaginous cap of an osteochondroma. EXT is genetically heterogeneous, and two genes, EXT1 and EXT2, located on 8q24 and 11p11-p12, respectively, have been cloned. It is still unclear whether osteochondroma is a developmental disorder or a true neoplasm. Furthermore, it is unclear whether inactivation of both alleles of an EXT gene, according to the tumor-suppressor model, is required for osteochondroma development, or whether a single EXT germline mutation acts in a dominant negative way. We therefore studied loss of heterozygosity and DNA ploidy in eight sporadic and six hereditary osteochondromas. EXT1- and EXT2-mutation analysis was performed in a total of 34 sporadic and hereditary osteochondromas and secondary peripheral chondrosarcomas. We demonstrated osteochondroma to be a true neoplasm, since aneuploidy was found in 4 of 10 osteochondromas. Furthermore, LOH was almost exclusively found at the EXT1 locus in 5 of 14 osteochondromas. Four novel constitutional cDNA alterations were detected in exon 1 of EXT1. Two patients with multiple osteochondromas demonstrated a germline mutation combined with loss of the remaining wild-type allele in three osteochondromas, indicating that, in cartilaginous cells of the growth plate, inactivation of both copies of the EXT1 gene is required for osteochondroma formation in hereditary cases. In contrast, no somatic EXT1 cDNA alterations were found in sporadic osteochondromas. No mutations were found in the EXT2 gene.  (+info)

Chemical modification and site-directed mutagenesis of conserved HXXH and PP-loop motif arginines and histidines in the murine bifunctional ATP sulfurylase/adenosine 5'-phosphosulfate kinase. (5/542)

The sulfurylase domain of the mouse bifunctional enzyme ATP sulfurylase/adenosine 5'-phosphosulfate (APS) kinase contains HXXH and PP-loop motifs. To elucidate the functional importance of these motifs and of conserved arginines and histidines, chemical modification and site-directed mutagenesis studies were performed. Chemical modification of arginines and histidines with phenylglyoxal and diethyl pyrocarbonate, respectively, renders the enzyme inactive in sulfurylase, kinase, and overall assays. Data base searches and sequence comparison of bifunctional ATP sulfurylase/APS kinase and monofunctional ATP sulfurylases shows a limited number of highly conserved arginines and histidines within the sulfurylase domain. Of these conserved residues, His-425, His-428, and Arg-421 are present within or near the HXXH motif whereas His-506, Arg-510, and Arg-522 residues are present in and around the PP-loop. The functional role of these conserved residues was further studied by site-directed mutagenesis. In the HXXH motif, none of the alanine mutants (H425A, H428A, and R421A) had sulfurylase or overall activity, whereas they all exhibited normal kinase activity. A slight improvement in reverse sulfurylase activity (<10% residual activity) and complete restoration of forward sulfurylase was observed with R421K. Mutants designed to probe the PP-loop requirements included H506A, R510A, R522A, R522K, and D523A. Of these, R510A exhibited normal sulfurylase and kinase activity, R522A and R522K showed no sulfurylase activity, and H506A had normal sulfurylase activity but produced an effect on kinase activity (<10% residual activity). The single aspartate, D523A, which is part of the highly conserved GRD sequence of the PP-loop, affected both sulfurylase and kinase activity. This mutational analysis indicates that the HXXH motif plays a role only in the sulfurylase activity, whereas the PP-loop is involved in both sulfurylase and kinase activities. Residues specific for sulfurylase activity have also been distinguished from those involved in kinase activity.  (+info)

Up-regulation of MDC15 (metargidin) messenger RNA in human osteoarthritic cartilage. (6/542)

OBJECTIVE: The aim of the study was to investigate the messenger RNA (mRNA) expression of the disintegrin metalloproteinase MDC15 (metargidin, or ADAM-15) in normal and osteoarthritic (OA) articular cartilage. METHODS: In situ hybridization experiments and reverse transcription-polymerase chain reaction (RT-PCR) were performed on tissue samples of adult normal and OA articular cartilage. RESULTS: MDC15 mRNA could be detected in normal articular cartilage by RT-PCR using tissue-extracted total RNA as a template. However, the mRNA level remained below the sensitivity of in situ hybridization. In contrast, in situ hybridizations of OA cartilage revealed an intense staining with the MDC15-specific riboprobes. The extension of the analysis to chondrosarcomas showed a strong up-regulation of MDC15 mRNA in these malignant transformed cells. CONCLUSION: Our results demonstrate a markedly strong up-regulation of MDC15 in adult OA and neoplastic cartilage compared with adult normal articular cartilage, indicating a potential role of the disintegrin metalloproteinase in cartilage remodeling.  (+info)

Reconstruction and limb salvage after resection for malignant bone tumour of the proximal humerus. A sling procedure using a free vascularised fibular graft. (7/542)

We assessed the intermediate functional results of eight patients after wide resection of the proximal humerus for malignant bone tumour. We used a free vascularised fibular graft as a functional spacer and a sling procedure to preserve passive scapulohumeral movement. Scapulohumeral arthrodesis was not carried out. Five patients had osteosarcoma, two achondrosarcoma and one a malignant fibrous histiocytoma of the bone. The mean duration of follow-up was 70 months (median, 76) for the seven patients who were still alive at the time of the latest follow-up. One patient died from the disease 12 months after surgery. There were no local recurrences. The functional results were described and graded quantitatively according to the rating system of the Musculoskeletal Tumour Society. Our results were satisfactory with regard to pain, emotional acceptance and manual dexterity. Function and lifting ability were unsatisfactory in two patients. One patient had delayed union between host and graft, but this united after six months without further surgery. Radiographs of the shoulder showed absorption or collapse of the head of the fibula in four of the eight patients and a fracture in another. No functional problems related to absorption or fracture of the head of the fibula were noted. There was no infection or subluxation of the head. We conclude that this is a reasonably effective technique of limb salvage after resection of the proximal humerus.  (+info)

Fusion of the EWS-related gene TAF2N to TEC in extraskeletal myxoid chondrosarcoma. (8/542)

Extraskeletal myxoid chondrosarcomas (EMCs) are characterized by a recurrent t(9;22)(q22;q12) translocation, resulting in the fusion of the EWS gene in 22q12 and the TEC gene in 9q22. Here we report that a third member of the EWS, TLS/FUS gene family, TAF2N, can replace EWS as a fusion partner to TEC in EMC. Two tumors, one with a novel t(9;17)(q22;q11) variant translocation and one with an apparently normal karyotype, expressed TAF2N-TEC fusion transcripts. In both cases, the chimeric transcripts were shown to contain exon 6 of TAF2N fused to the entire coding region of TEC. This transcript is structurally and functionally very similar to the EWS-TEC fusions. The exchange of the EWS NH2-terminal part with the TAF2N NH2-terminal part in EMC further underscores the oncogenic potential of these protein domains as partners in fusion genes.  (+info)

Chondrosarcoma is a type of highly malignant tumor with a potent capacity to invade locally and cause distant metastasis. Chondrosarcoma shows a predilection for metastasis to the lungs. Interleukin-8 (IL-8), a chemokine with a defining CXC amino acid motif, is known to possess tumorigenic and proangiogenic properties. Over-expression of IL-8 has been detected in many human tumors. However, the effects of IL-8 in migration and integrin expression in chondrosarcoma cells are largely unknown. In this study, we found that IL-8 increased the migration and the expression of αvβ3 integrin in human chondrosarcoma cells. Activations of phosphatidylinositol 3-kinase (PI3K), Akt, and AP-1 pathways after IL-8 treatment were demonstrated, and IL-8-induced expression of integrin and migration activity was inhibited by the specific inhibitor and mutant of PI3K, Akt, and AP-1 cascades. Taken together, our results indicated that IL-8 enhances the migration of chondrosarcoma cells by increasing αvβ3 integrin ...
article{52f6a2c0-7074-42f4-ae84-0c0dbf6711b3, abstract = {,p,Rat chondrosarcoma chondrocytes were labeled with [,sup,3,/sup,H]serine or [,sup,3,/sup,H]mannose as a precursor. Intracellular proteoglycan core protein precursor was purified from cell lysates by immunoprecipitation with polyclonal antibodies against the hyaluronic acid-binding region, followed by sodium dodecyl sulfate-polyacrylamide gel electrophoresis. The core precursor was eluted from the gels and treated with alkaline borohydride in order to convert serine residues substituted with xylose or N-acetylgalactosamine to alanine (or with alkaline sulfite to convert them to cysteic acid). After acid hydrolysis, the proportions of labeled serine and alanine (or cysteic acid) were determined by high performance liquid chromatography, and the results were compared with those obtained for the completed proteoglycan molecules isolated from the same cultures. In the completed proteoglycans, about 55% of the serine residues were substituted ...
OBJECTIVE: To determine whether, in human fibroblasts and chondrosarcoma cells, the regulation of interleukins (IL)-6, 8, and 11 and matrix metalloproteinases (MMP)-1, 3, and 13, and their tissue inhibitor TIMP-1, depends on the transcription factor nuclear factor-kappaB (NF-kappaB). METHODS: Fibroblasts and chondrosarcoma cells were effectively infected with an adenovirus encoding human IkappaBalpha, and inhibition of NF-kappaB function was observed. The induction of MMP and IL-6, 8, and 11 by various stimuli was assessed by ELISA. RESULTS: The induction of IL-6 and IL-8 clearly depended on NF-kappaB in both fibroblasts and chondrosarcoma cells, irrespective of stimulus, but IkappaBalpha overexpression had little effect on IL-11. MMP-1, -3, and -13 were also inhibited, but TIMP-1 was unaffected. CONCLUSION: NF-kappaB appears to play an important and selective role in MMP induction in human fibroblasts and chondrosarcoma cells. This suggests there are NF-kappaB dependent mechanisms of cartilage
OBJECTIVE: To determine whether, in human fibroblasts and chondrosarcoma cells, the regulation of interleukins (IL)-6, 8, and 11 and matrix metalloproteinases (MMP)-1, 3, and 13, and their tissue inhibitor TIMP-1, depends on the transcription factor nuclear factor-kappaB (NF-kappaB). METHODS: Fibroblasts and chondrosarcoma cells were effectively infected with an adenovirus encoding human IkappaBalpha, and inhibition of NF-kappaB function was observed. The induction of MMP and IL-6, 8, and 11 by various stimuli was assessed by ELISA. RESULTS: The induction of IL-6 and IL-8 clearly depended on NF-kappaB in both fibroblasts and chondrosarcoma cells, irrespective of stimulus, but IkappaBalpha overexpression had little effect on IL-11. MMP-1, -3, and -13 were also inhibited, but TIMP-1 was unaffected. CONCLUSION: NF-kappaB appears to play an important and selective role in MMP induction in human fibroblasts and chondrosarcoma cells. This suggests there are NF-kappaB dependent mechanisms of cartilage ...
55 year old male with dedifferentiated chondrosarcoma and pathological fracture. Final Diagnosis: Left proximal femur and soft tissues, en bloc excision: Dedifferentiated chondrosarcoma High grade, grade 3/3 Maximum size 14.6 cm Tumor is ba...
Cyclooxygenase (COX)-2, the inducible isoform of prostaglandin (PG) synthase, has been implicated in tumor metastasis. Interaction of COX-2 with its specific EP receptors on the surface of cancer cells has been reported to induce cancer invasion. However, the effects of COX-2 on migration activity in human chondrosarcoma cells are mostly unknown. In this study, we examined whether COX-2 and EP interaction are involved in metastasis of human chondrosarcoma. We found that over-expression of COX-2 or exogenous PGE2 increased the migration of human chondrosarcoma cells. We also found that human chondrosarcoma tissues and chondrosarcoma cell lines had significant expression of the COX-2 which was higher than that in normal cartilage. By using pharmacological inhibitors or activators or genetic inhibition by the EP receptors, we discovered that the EP1 receptor but not other PGE receptors is involved in PGE2-mediated cell migration and α2β1 integrin expression. Furthermore, we found that human
Human chondrosarcomas do not respond to current chemotherapies or radiation therapy, and their size and histological appearance do not reliably predict the risk of local recurrence and metastases, making selection of surgical treatment difficult. Identifying mechanisms responsible for the proliferation and invasive behavior of these tumors would be of immense clinical value. We hypothesized that telomerase expression is one of these mechanisms. We detected telomerase expression in 7 of 16 chondrosarcomas, but cells cultured from telomerase-negative chondrosarcomas acquired strong telomerase activity and lost tumor suppressor activity after their establishment in culture. These changes were associated with accelerated indefinite cell proliferation, morphological transition, and increased invasive activity, indicating that telomerase activation and loss of cell cycle control leads to the emergence of aggressive cells from chondrosarcoma cell populations. These observations may lead to better ...
In this study, we investigated the anticancer effects of a new benzimidazole derivative, 1-benzyl-2-phenyl -benzimidazole (BPB), in human chondrosarcoma cells. BPB-mediated apoptosis was assessed by the MTT assay and flow cytometry analysis. The in vivo efficacy was examined in a JJ012 xenograft model. Here we found that BPB induced apoptosis in human chondrosarcoma cell lines (JJ012 and SW1353) but not in primary chondrocytes. BPB induced upregulation of Bax, Bad and Bak, downregulation of Bcl-2, Bid and Bcl-XL and dysfunction of mitochondria in chondrosarcoma. In addition, BPB also promoted cytosolic releases AIF and Endo G. Furthermore, it triggered extrinsic death receptor-dependent pathway, which was characterized by activating Fas, FADD and caspase-8. Most importantly, animal studies revealed a dramatic 40% reduction in tumor volume after 21 days of treatment. Thus, BPB may be a novel anticancer agent for the treatment of chondrosarcoma.
BioAssay record AID 79237 submitted by ChEMBL: In vitro cytotoxicity in chondrosarcoma cell line (H-EMC-SS) by Alamar blue assay.
Clear cell chondrosarcoma is a rare tumor that can be easily confused with benign tumors. The aim of this report is to present a case that is rare, initially diagnosed as aneurysmal bone cyst and then chondroblastoma, and has an interesting extension pattern. A 41-year-old male patient was treated for an apparently benign cystic lesion of the right proximal femur by intralesional excision and bone grafting. The pathological diagnosis was aneurysmal bone cyst. Two years later, the patient presented with a pathological fracture at the same site and a total hip arthroplasty was performed. The pathological specimen was diagnosed as chondroblastoma. Three years later, clinical and radiological examination of the patient revealed a large mass located on the intrapelvic side of the acetabulum. There was no evidence of distant metastases. Both tumors were resected with a wide margin on the femoral side and a marginal margin on the intrapelvic side. The extremity was reconstructed with a resection-type ...
Chondrosarcomas are malignant cartilage tumors that do not respond to traditional chemotherapy or radiation. The 5-year survival rate of histologic grade III chondrosarcoma is less than 30%. To achieve a greater understanding of chondrosarcoma tumorigenesis, a model for human chondrosarcoma has been established in a rat system. The model, known as the Swarm rat chondrosarcoma (SRC), resembles human chondrosarcoma and provides a system to study tumor growth and progression. Here we examined the influence of the tumor microenvironment and the impact of genome-wide hypomethylation on the behavior of SRC tumors, two factors known to contribute fundamentally to the development and progression of solid tumors. Previous studies with SRC revealed that tumor microenvironment can significantly influence chondrosarcoma malignancy, but the underlying biologic mechanisms have not been defined. To address this issue we carried out epigenetic and gene expression studies on the SRC tumors that were initiated at
PubMed comprises more than 30 million citations for biomedical literature from MEDLINE, life science journals, and online books. Citations may include links to full-text content from PubMed Central and publisher web sites.
Bone: Dedifferentiated chondrosarcoma, Authors: Andreas F Mavrogenis, Panayiotis J Papagelopoulos. Published in: Atlas Genet Cytogenet Oncol Haematol.
Primary chondrosarcoma of the breast, although very rare, has been reported previously.1 An extensive review of 132 636 cases of breast cancer between 1973 and 1998, in the Netherlands,2 identified 34 cases of concurrent breast cancer and cartilaginous tumours. There were 28 osteochondromas in the same group as well but a statistically similar incidence of concurrent osteochondromas was observed in patients with lung cancer. Out of the 34 cases, 18 were enchondromas and 15 chondrosarcomas, and involved mostly the femur or humerus (65%). All 34 had histological and immunohistochemical survey performed and cluster analysis did not reveal any associations with known syndromes or genetic traits. Their findings support the existence of a new hitherto unrecognised syndrome, characterised by an increased risk to develop breast cancer and also centrally originating cartilaginous tumours. There have been sporadic reports of concurrent breast carcinoma as well as bone chondrosarcoma in the literature.3 ...
Cartilage tumors vary in severity from benign enchondroma to low-grade malignant chondrosarcoma to the highest-grade dedifferentiated chondrosarcoma. Chondrosarcoma is the second most common primary malignant bone tumor, accounting for 10-20% of all primary bony malignancies.
Kevin B. Jones, MD of University of Utah - Huntsman Cancer Institute receives grant for Polarity and Ploidy in Peripheral Chondrosarcoma research.
TY - JOUR. T1 - Antitumor Effects and Distribution of Adriamycin Incorporated into Hydroxyapatite Implants in a Cancer Rat Model Bearing Swarm Rat Chondrosarcoma. AU - Yamamura, Keiko. AU - Osada, Takashi. AU - Nabeshima, Toshitaka. AU - Iwata, Hisashi. AU - Yotsuyanagi, Toshihisa. PY - 1994. Y1 - 1994. N2 - We investigated the antitumor effects and tissue distribution of adriamycin (ADR) incorporated into a hydroxyapatite (HAP) bead in a cancer rat model bearing Swarm rat chondrosarcoma. The Porous HAP bead (8.48 mm in diameter, 531 ±0.7 mg in weight) was used as a model bone graft. One ADR-HAP bead (ADR 0.4 mg-6.0 mg/bead) was implanted s.c. into a Sprague-Dawley rat at 6 days postinoculation of Swarm rat chondrosarcoma. ADR-HAP beads showed strong antitumor activities in a dose dependent manner. The dose of 6.0 mg/bead showed the highest efficacy with no toxic death: It caused a 98% growth inhibition on Day 31 postinoculation and a survival advantage of a 339% increase in life span. After ...
Imaging studies - including radiographs (x-rays), computerized tomography (CT), and magnetic resonance imaging (MRI) - are often used to make a presumptive diagnosis of chondrosarcoma. However, a definitive diagnosis depends on the identification of malignant cancer cells producing cartilage in a biopsy specimen that has been examined by a pathologist. In a few cases, usually of highly anaplastic tumors, immunohistochemistry (IHC)is required.. There are no blood tests currently available to enable an oncologist to render a diagnosis of chondrosarcoma. The most characteristic imaging findings are usually obtained with CT.. Nearly all chondrosarcoma patients appear to be in good health. Often, patients are not aware of the growing tumor until there is a noticeable lump or pain. Earlier diagnosis is generally accidental, when a patient undergoes testing for another problem and physicians discover the cancer. Occasionally the first symptom will be a broken bone at the cancerous site. Any broken ...
Chondrosarcomas are a primitive malignant tumor that derives from cartilage cells. It usually appears at the center of a bone segment, with no pre-existing lesions (central chondrosarcoma). It may also be secondary to a pre-existent condition suc...
Gentaur molecular products has all kinds of products like :search , US Biomax \ Osteosarcoma and chondrosarcoma tissue array, with stage, grade and TNM data, 80 cases_80 cores, replacing OS801 and BC26111; ihc Anti-Actin confirmed \ OS802 for more molecular products just contact us
We report an unusual case of a young woman with chondrosarcoma affecting the greater cornu of the hyoid bone. Only a handful of reports of primary chondrosarcoma involving the hyoid exist in the world literature. The case described presented as a swe
Chondrosarcoma are a relatively rare neoplasia observed in cattle. The disease involves neoplastic changes to chondrocytes involved with cartilage growth, maintenance and remodeling of cartilage. In abattoir surveys, the frequency of malignant or benign cartilaginous neoplasms in cattle has been found to be less than 1% of all neoplasms[1]. The cause of this disease is unknown but likely to involve genetics. Chondrosarcoma usually affect axial bones rather than appendicular ones, and flat bones are involved more often than long bones. Chondrosarcoma have been commonly reported in the scapula of cattle with no apparent breed predilection[2]. Other sites include the nasal turbinates[3] and extraskeletal sites such as the mesenchyme[4]. Lameness is usually the first presenting clinical sign, and as the condition worsens, obvious swelling around the tumour becomes apparent. In tumours involving the nasal turbinates, a nasal discharge and dyspnea may be apparent. Diagnosis can only be made after ...
As for the genetics and causes of the cancer, it has been rather hard to find sources which can determine the cause of it, from the website…. The genetic changes specific to chondrosarcoma continue to be investigated extensively. Although studies have not yet established a specific or recurrent karyotypic feature for any of these tumors, different chondrosarcomas have demonstrated anomalies in several tumor suppressor genes, oncogenes, and transcription factors, including TP53, RAS, EXT1, EXT2, and Sox9. Available cytogenetic and comparative genomic hybridization (CGH) studies reveal changes in some chondrosarcomas, but fail to do so in others. These studies are thus far difficult to interpret.. Based on the available studies, it is likely that chondrosarcomas are generated by a coordinated, multi-step process involving primarily tumor suppressor genes. In fact, the complexity and variety of genetic changes seen in chondrosarcomas may indicate several distinct genetic pathways. Some of the ...
Sarcoma is a peer-reviewed, Open Access journal dedicated to publishing papers covering all aspects of connective tissue oncology research. It brings together work from scientists and clinicians carrying out a broad range of research in this field, including the basic sciences, molecular biology and pathology and the clinical sciences of epidemiology, surgery, radiotherapy and chemotherapy. High-quality papers concerning the entire range of bone and soft tissue sarcomas in both adults and children, including Kaposis sarcoma, are published as well as preclinical and animal studies.
Chondrosarcoma is a type of cancer that develops in cartilage cells. Cartilage is the specialized, gristly connective tissue that is present in adults and the tissue from which most bones develop. Cartilage plays an important role in the growth process. There are many different types of cartilage that are present throughout the body. Chondrosarcoma is a malignant type of bone cancer that primarily affects the cartilage cells of the femur (thighbone), arm, pelvis, and knee. Although less frequent, other areas (such as the ribs) may be affected.. Chondrosarcoma is the second most common type of primary bone cancer. A primary bone cancer is one that originates from bone, as opposed to starting in another organ and then spreading to the bone. This type of cancer rarely affects individuals under age 20 and continues to rise until age 75. The incidence between males and females is equal.. ...
Chondrosarcoma is a type of cancer that develops in cartilage cells. Cartilage is the specialized, gristly connective tissue that is present in adults and the tissue from which most bones develop. Cartilage plays an important role in the growth process. There are many different types of cartilage that are present throughout the body. Chondrosarcoma is a malignant type of bone cancer that primarily affects the cartilage cells of the femur (thighbone), arm, pelvis, and knee. Although less frequent, other areas (such as the ribs) may be affected.. Chondrosarcoma is the second most common type of primary bone cancer. A primary bone cancer is one that originates from bone, as opposed to starting in another organ and then spreading to the bone. This type of cancer rarely affects individuals under age 20 and continues to rise until age 75. The incidence between males and females is equal.. ...
Chondrosarcoma can be of several types depending on the type of cells which are present in the tumor and how they appear microscopically. It is composed of transformed cells that produce cartilage. Radiograph of the head revealed lytic lesion with endosteal scalloping (A, arrow) and…, CT scan showed bone destruction of the skull (A) and matrix calcification (A,…, Transverse T1-weighted MRI (A) and its contrastenhanced image (C) showed a slightly low-signal…, Histopathological finding revealed proliferation of…, Histopathological finding revealed proliferation of the atypical chondrocytes (arrows) and cartilaginous component (C).…, NLM Clipboard, Search History, and several other advanced features are temporarily unavailable. Chondrosarcoma that occurs in a long bone of the leg, for example, is typically treated with the amputation of that leg. , Chondrosarcoma is a malignant tumor of the category known as sarcomas. Various types of cancer can affect the skeletal system, and an ...
TY - JOUR. T1 - Chondrosarcoma. T2 - Its treatment by radiation, hyperthermia and bleomycin. AU - Okuyama, S.. AU - Itoh, M.. AU - Tanaka, K.. AU - Matsuzawa, T.. PY - 1978/12/1. Y1 - 1978/12/1. N2 - A case of chondrosarcoma of the mandible of surgical failure was treated by radiation, hyperthermia, and bleomycin. The treatment resulted in selective necrosis of the tumor. This can be designated as perpetuation principle of radiothermotherapy because bleomycin may inhibit the repair processes of heat and radiation damage. This principle appears to offer selectivity of the therapeutic effects, to open a way to treatment of those radioresistant selectivity of the therapeutic effects, open a way to treatment of those radioresistant malignancies, and to enhance curability of various medium-sensitive tumors. Additionally, a course of large-dose glutathione infusion was confirmed to promptly alleviate radiation dermatitis and mucositis.. AB - A case of chondrosarcoma of the mandible of surgical failure ...
TY - JOUR. T1 - Electrophoretic and serologic characterization of 56 kDa antigen (M56) with autologous serum derived from a chondrosarcoma patient. T2 - A shared antigen of immunoresponses in cancer and autoimmune diseases. AU - Fujiwara, Kazuo. AU - Udono, Heiichiro. AU - Kunisada, Toshiyuki. AU - Kawai, Akira. AU - Inoue, Hajime. AU - Takigawa, Masaharu. AU - Namba, Masayoshi. AU - Nakayama, Eiichi. PY - 1999. Y1 - 1999. N2 - We investigated whether antibodies specific to autologous cancer cells are produced in the peripheral blood of patients with chondrosarcoma. There have been few reports on the investigation of the immune responses, such as autologous antibody production, to chondrosarcoma. Here, tumor-associated antigens were separated by sodium dodecyl sulfate (SDS)-polyacrylamide gel electrophoresis and detected by immunoenzymatic amplification. A 56 kDa molecule (M56) was detected in the serum from patients peripheral blood. M56 is ubiquitously expressed in various kinds of ...
Get information, facts, and pictures about Chondrosarcoma at Encyclopedia.com. Make research projects and school reports about Chondrosarcoma easy with credible articles from our FREE, online encyclopedia and dictionary.
Supplementary Material for: MiR-129-5p Inhibits Proliferation and Invasion of Chondrosarcoma Cells by Regulating SOX4/Wnt/β-Catenin Signaling Pathway
At Erasmus, our vision is to become the leading Professional Congress Organiser in Greece and one of the top ten Professional Congress Organisers globally, while conducting our business with professionalism, ethics and responsibility towards our people (personnel), our clients and the society ...
A case of an entirely intramuscular mixed tumour occurred in an 82-year-old man, who presented with a large mass in the region of the right triceps muscle. A lobulated tumour was seen, with plump, round epithelioid cells embedded in a chondromyxoid stroma. Immunohistochemical examination showed strong S100 protein and pancytokeratin positivity in most of the tumour cells. Cytogenetic analysis revealed complex clonal chromosomal changes: 47, XY, +i(2) (q10), -15, der(17) t(15; 17) (q11; p12), +r. Differential diagnosis against extraskeletal myxoid chondrosarcoma (EMC) may be problematic, particularly in an incisional biopsy. Chromosomal analysis can be very helpful in solving this problem, since EMC shows a specific reciprocal chromosome translocation characterised as t (9;22) (q22-31) (q11-12 ...
Chondrosarcoma is categorized as a malignant cartilaginous tumor, which occurs rarely in the craniofacial region. We report the case of a 68-year-old man with chondrosarcoma in the subglottic area. His chief symptoms were hoarseness and mild dysphagi
Purpose: Chondrosarcomas are notoriously resistant to cytotoxic chemotherapeutic agents. We sought to identify critical signaling pathways that contribute to their survival and proliferation, and which may provide potential targets for rational therapeutic interventions. Experimental Design: Activation of receptor tyrosine kinases (RTKs) was surveyed using phospho-RTK arrays. S6 phosphorylation and NRAS mutational status were examined in chondrosarcoma primary tumor tissues. Small interfering RNA or small molecule inhibitors against RTKs or downstream signaling proteins were applied to chondrosarcoma cells and changes in biochemical signaling, cell cycle, and cell viability were determined. In vivo anti-tumor activity of BEZ235, a phosphoinositide-3-kinase (PI3K)/mammalian target of rapamycin (mTOR) inhibitor, was evaluated in a chondrosarcoma xenograft model. Results: Several RTKs were identified as critical mediators of cell growth, but the RTK dependencies varied among cell lines. In ...
Although a rare entity, chondrosarcoma is the most common malignant tumor of the chest wall. Most patients present with an enlarging, painful anterior chest wall mass arising from the costochondrosternal junction. CT scan with intravenous contrast is the gold standard radiographic study for diagnosis and operative planning. Contrary to previous dictum, resection may be performed in an appropriate surgical candidate based on imaging characteristics or image-guided percutaneous biopsy results; incisional biopsy is rarely required. The keys to successful treatment are early recognition and radical excision with adequate margins, as chondrosarcoma is relatively resistant to radiotherapy and conventional cytotoxic chemotherapy. Overall survival is excellent in most surgical series from experienced centers. Complete excision with widely negative microscopic margins at the initial operation is of the utmost importance, as local recurrence portends systemic metastasis and eventual tumor-related mortality. This
Clear-cell chondrosarcoma is a variant of chondrosarcoma which is characterized by a typical histomorphology and a very slow rate of growth. A case is presented in which the tumor was located in the maxilla. show less ...
A chondrosarcoma in the anterior mediastinum is a rare finding with a relatively good prognosis. We describe a case of a 75-year-old man with a 2-year history of neck discomfort and weight loss. Imaging showed a homogenous tumor with a minor compression on the anterior part of the heart. It had close relation to the ribs, no surrounding fat, and a thymoma was suspected. Biopsy prior to surgery was impossible due to the location of the tumor. Unfortunately, final pathology from the surgical specimen revealed a chondrosarcoma. ...
BACKGROUND: notch receptors are critical determinants of cell fate in a variety of organisms. Notch signaling is involved in the chondrogenic specification of neural crest cells. Aberrant Notch activity has been implicated in numerous human diseases including cancers; however its role in chondrogenic tumors has not been clarified. METHOD: tissue samples from a case of primary chondrosarcoma of the maxilla and its recurrent tumor were examined immunohistochemically for Notch1-4 and their ligands (Jagged1, Jagged2 and Delta1) expression. RESULTS: both primary and recurrent tumors were histopathologically diagnosed as conventional hyaline chondrosarcoma (WHO Grade I). Hypercellular tumor areas strongly expressed Notch3 and Jagged1 in spindle and pleomorphic cells suggesting up-regulation of these protein molecules at sites of tumor proliferation. Expression patterns were distinct with some overlap. Differentiated malignant and atypical chondrocytes demonstrated variable expression levels of ...
Answer: Chondrosarcoma. Histology: none provided. Discussion: Chondrosarcomas are malignant proliferations of cartilage which tend to occur in the axial skeleton of older people. The radiograph in this case is helpful to diagnose a malignant tumor because of its destructive and aggressive permeative pattern. Histologically the cartilage shows atypical nuclei and a permeative growth pattern around native trabeculae. This permeative growth pattern is diagnostic of malignancy in most primary bone tumors. The radiograph, however, is a most important tool leading to the diagnosis of chondrosarcoma.. Although metastatic carcinoma is the most common bone tumor in this age group, there is no evidence of epithelial cells in this case.. Enchondromas occasionally occur in the pelvis. Occasionally, the cartilage of enchondroma can show atypia. However, the destructive and aggressive radiographic pattern precludes the diagnosis of an enchondroma. Therefore, the radiograph should always be consulted when ...
TY - JOUR. T1 - An extraskeletal chondrosarcoma of the maxilla. A case report. AU - Nishioka, Gary. AU - Holt, G. Richard. AU - Aufdemorte, Thomas B.. AU - Triplett, Robert G.. PY - 1995/2. Y1 - 1995/2. UR - http://www.scopus.com/inward/record.url?scp=0028858834&partnerID=8YFLogxK. UR - http://www.scopus.com/inward/citedby.url?scp=0028858834&partnerID=8YFLogxK. U2 - 10.1016/0278-2391(95)90401-8. DO - 10.1016/0278-2391(95)90401-8. M3 - Article. C2 - 7830187. AN - SCOPUS:0028858834. VL - 53. SP - 193. EP - 195. JO - Journal of Oral and Maxillofacial Surgery. JF - Journal of Oral and Maxillofacial Surgery. SN - 0278-2391. IS - 2. ER - ...
Chondrosarcomas are characteristic for their slow but progressive invasion of the surrounding tissues. These malignant, cancerous tumors originate in the cartilage, the connective tissue between bones.
Depending on the type of chondrosarcoma, it may spread slowly or very rapidly. Its presently unknown what causes this type of cancer. This is partially because it is so unusual that there are not a lot of cases to study. A higher incidence of nasal CSAs among cats living in urban areas may indicate a link to air pollution. The type affecting bones has been found to contain viruses in the cells of the tumor, suggesting a viral connection. Some bone tumors develop on the site of a previous fracture, which may mean theres a link with the bodys cells that heal a broken bone. But its believed that several factors combine with each unique cats physiology to cause the cells to become cancerous ...
Reconstruction of Acetabular Wall Using Autologous Bone Graft Following Resection of Pelvic Chondrosarcoma: Surgical Technique and Functional Outcome
Rare Cancer News & Clinical Trials » Trial - Sarcoma » Anti-Osteoclast Therapy as Neoadjuvant in Treatment of Chondrosarcoma - Phase 1b ...
A chondrosarcoma is one of several types of laryngeal tumors that can effect the larynx and trachea of a dog. This is a relatively rare and fast spreading tumor that originates in the cartilage, a connective collagenous tissue that is found throughout the body.
Chondrosarcoma is a malignant type of bone cancer that primarily affects the cartilage cells of the femur, arm, pelvis, knee, and spine.
Chondrosarcoma is a malignant type of bone cancer that primarily affects the cartilage cells of the femur, arm, pelvis, knee, and spine.
Chondrosarcoma treatments include chemotherapy, radiation therapy, targeted therapies, and surgery, to remove the mass and reduce the likelihood of return.
MSH: A slowly growing malignant neoplasm derived from cartilage cells, occurring most frequently in pelvic bones or near the ends of long bones, in middle-aged and old people. Most chondrosarcomas arise de novo, but some may develop in a preexisting benign cartilaginous lesion or in patients with ENCHONDROMATOSIS. (Stedman, 25th ed),NCI: A type of cancer that forms in bone cartilage. It usually starts in the pelvis (between the hip bones), the shoulder, the ribs, or at the ends of the long bones of the arms and legs. A rare type of chondrosarcoma called extraskeletal chondrosarcoma does not form in bone cartilage. Instead, it forms in the soft tissues of the upper part of the arms and legs. Chondrosarcoma can occur at any age but is more common in people older than 40 years. It is a type of bone cancer.,NCI: A malignant mesenchymal neoplasm arising from cartilage-forming tissues.,NCI: A malignant tumor with pure hyaline cartilage differentiation. Myxoid changes, calcification and ossification ...
TY - JOUR. T1 - Intracranial extraskeletal mesenchymal chondrosarcoma. T2 - Case report. AU - Bingaman, Kimberly D.. AU - Alleyne, Cargill H.. AU - Olson, Jeffrey J.. PY - 2000/1. Y1 - 2000/1. N2 - OBJECTIVE AND IMPORTANCE: We present a patient with a dural-based intracranial extraskeletal mesenchymal chondrosarcoma, which was initially thought to be an atypical meningioma. This rare tumor should be considered in the differential diagnosis of young adults with an aggressive-appearing dural-based lesion. CLINICAL PRESENTATION: A 21-year-old woman reported a 3- week history of severe headaches and intermittent nausea and vomiting. Neurological examination revealed right optic nerve swelling. Magnetic resonance imaging demonstrated a large, intensely enhancing extra-axial mass, which appeared to originate from the right side of the falx cerebri with significant mass effect. A presumptive diagnosis of meningioma was made. INTERVENTION: The patient underwent preoperative embolization of the lesion ...
Myxofibrosarcoma (MFS) is characterized by abundant myxoid stroma, a wide spectrum of cytological atypia, and frequent local recurrence. Some soft tissue tumors with myxoid stroma can histologically mimic MFS, but have different biological behaviors. Here we sought to identify a useful diagnostic marker for MFS. After our analysis of the gene expression dataset from the Gene Expression Omnibus database, we focused on claudin 6 (CLDN 6). The status of CLDN 6 was assessed by immunohistochemistry in 61 samples of MFS and other (benign) myxoid soft tissue tumors (28 myxoma samples, 12 nodular fasciitis samples), 18 low-grade fibromyxoid sarcoma, 30 myxoid liposarcoma, 29 extraskeletal myxoid chondrosarcoma and 27 dedifferentiated liposarcoma with myxoid feature samples ...
BACKGROUND: The finding of a cytogenetic-pathologic correlation between complex karyotypes and high grade cartilaginous tumors has been reported. However, few cytogenetic reports exist regarding benign or low grade lesions. A subset of low grade malignant cartilaginous tumors is characterized by locally aggressive behavior but no metastatic potential. Because the histopathologic distinction between benign, borderline, or low grade malignant cartilaginous lesions can be difficult, the finding of additional tumor markers associated with the clinical behavior of borderline cartilaginous lesions could be clinically significant.. METHODS: Four cartilaginous tumors, including an osteochondroma (OC), a chondromyxoid fibroma (CF), an enchondroma (EC), and a dedifferentiated chondrosarcoma (DCS), were cultured and harvested using short term, in situ culture techniques. Chromosome analysis was performed by conventional G-banding and fluorescence in situ hybridization was used to confirm ...
TY - JOUR. T1 - Molecular phenotyping of HCS-2/8 cells as an in vitro model of human chondrocytes. AU - Saas, J.. AU - Lindauer, K.. AU - Bau, B.. AU - Takigawa, M.. AU - Aigner, Thomas. N1 - Funding Information: Funding sources: This work was supported by the BMBF (grant 01GG9824) and Aventis Pharma Deutschland GmbH. Funding Information: This work was supported by the BMBF (grant 01GG9824) and Aventis Pharma Deutschland GmbH. We are grateful to Drs M.B. Goldring (Boston) and J. Block (Chicago) for the chondrocyte cell lines C28I2 and C28a4 as well as AG and SG. The SW1353 chondrosarcoma cell line was obtained by ATCC (Manassas, Virginia, USA).. PY - 2004/11. Y1 - 2004/11. N2 - Objective: Cultures of primary articular chondrocytes for studying chondrocyte biology are notoriously difficult to handle. One alternative is the use of chondrocytic cell lines. Because the HCS-2/8 cells are the most widely used cell line in cartilage research, we investigated the molecular phenotype of these cells by ...
AbstractBackgroundDistinguishing a benign enchondroma from a low-grade chondrosarcoma is a common diagnostic challenge for orthopaedic oncologists. Low interrater agreement has been observed for the diagnosis of cartilaginous neoplasms among radiologists and pathologists, but, to our knowledge, no s
Twenty-eight patients with histologically confirmed chordomas (18) or chondrosarcomas (10) underwent Gamma Knife SRS either as primary or adjuvant treatment. Their ages ranged from 17 to 72 years (median 44 years). The most common presenting symptom was diplopia (26 patients, 93%). In two patients, SRS was the sole treatment. Twenty-six patients underwent between one and five additional surgical procedures. Two underwent an initial trans-sphenoidal biopsy. The average tumor volume was 9.8 cm3. The median dose to the tumor margin was 16 Gy. ...
Published papers: 1. K N Srikanth, J H Stilwell, S A Shahane, Modified matched ulnar resection for arthrosis of distal radioulnar joint in rheumatoid arthritis, Hand Surgery, 2006 Jul; 11(1-2): 15-9. PMID:17080523 2. K N Srikanth, M Chong, K Porter. Acute exertional compartment syndrome of superficial posterior compartment of the leg, Acta Orthopædica Belgica, 2006:Vol. 72 -4:507-510. 3. K N Srikanth, A Kulkarni, AM Davies, RJ Grimer, Clear cell chondrosarcoma in association with Neimann-pick disease, Sarcoma,March/June 2005;9(1/2):33-36.A Gadgil, R Dias, 4. K.N. Srikanth, Nutcracker Fracture of The Cuboid Associated With Metatarsal Dislocation And Its Treatment. The Internet Journal of Orthopedic Surgery. 2006. Volume 3 Number 1. 5. Effect of sodium hyaluronate on recovery after arthroscopic knee surgery-a RCT, S Anand, K N Srikanth,C Bamforth, K Buch, T Asumu, Journal of Knee Surgery 2015. ...
MULLER, Daniel Curvello de Mendonça et al. Hemipelvectomy in the treatment of chondrosarcoma of the acetabulum dog. Cienc. Rural [online]. 2010, vol.40, n.5, pp.1218-1222. ISSN 1678-4596. http://dx.doi.org/10.1590/S0103-84782010000500036.. Hemipelvectomy is the removal of part of the pelvis and is indicated for the surgical treatment of malignant tumors. This study presents the case of a canine patient with recurrent chondrosarcoma, submitted to hemipelvectomy with limb amputation. The report aims to highlight the importance of surgery in the treatment of radial bone chondrosarcoma, addressing a viable and unconventional alternative for patients suffering from tumors in the pelvis, which against the extension of the lesion may be misdiagnosed as intractable cancer. After the partial hemipelvectomy with amputation of the limb the animal satisfactory returned to ambulation without difficulty in supporting or alteration in balance.. Keywords : neoplasm; pelvis; cancer surgery; dogs. ...
We should be careful in open reduction and internal fixation of fracture and also should consider in mind the diagnosis of pseudoaneurysm during plate removal,
Pain is the usual presenting symptom; alternatively the tumour may be found incidentally on imaging. Signs are localise to the involved bone. Imaging appearances are difficult as most chondrosarcomas resemble benign chondroma. The most common features are of central lucency with expansion and thickening of the overlying cortex.. ...
Chondroid tumors are predominantly lesions of the axial skeleton but can infrequently have an extraskeletal origin. Primary intracranial chondrosarcomas constitute ,0.16% of all brain tumors, an overwhelming majority of which are skull base tumors (1, 2). They are thought to arise from undifferentiated cells from cartilaginous synchondroses (1-3, 6, 7). Much less common sites include the falx, choroid plexus, and convexity. The histogenesis at this site is uncertain but is thought to arise from the pluripotent cells of the meninges.. Primary chondrosarcomas can be classified as mesenchymal, myxoid, or classical based on their cytoarchitecture. In the series published by Korten et al (2), which included 15 case reports plus 177 cases from a review of the literature, no sex dominance was shown. Ages varied from 3 months to 76 years, with a mean age of 37 years. Considering the rarity of occurrence of intracranial chondrosarcomas, it was difficult to establish a clear demographic pattern; however, ...
Endosteal scalloping of the cortical bone can be seen in benign lesions like FD and low-grade chondrosarcoma.. The images on the left show irregular cortical destruction in an osteosarcoma (left) and cortical destruction with aggressive periosteal reaction in Ewings sarcoma.. ...
TBX3, a member of the T-box family of transcription factors, is essential in development and has emerged as an important player in the oncogenic process. TBX3 is overexpressed in several cancers and has been shown to contribute directly to tumour formation, migration and invasion. However, little is known about the molecular basis for its role in development and oncogenesis because there is a paucity of information regarding its target genes. The cyclin-dependent kinase inhibitor p21WAF1 plays a pivotal role in a myriad of processes including cell cycle arrest, senescence and apoptosis and here we provide a detailed mechanism to show that it is a direct and biologically relevant target of TBX3. Using a combination of luciferase reporter gene assays and in vitro and in vivo binding assays we show that TBX3 directly represses the p21WAF1 promoter by binding a T-element close to its initiator. Furthermore, we show that the TBX3 DNA binding domain is required for the transcriptional repression of p21WAF1
223 the preoperative magnetic resonance imaging in the midline, the submandibular salivary gland tumors, have a low-grade chondrosarcoma of the subglottic airway is essential for speech, mastication, and swallowing can be done until an adequate distance to the enormous psychological strain placed on the care of a patient with extensive bilateral retinoblastoma are associated with an accurate basis for 3 weeks postpartum, and kegel abilify withdrawal causes mania exercises to improve functional recovery of function in this older man, with an. 3. Patients may become bilateral. Diagnostic evaluation 1. Cbc with platelets. 1. Further management of st-elevation myocardial infarction: A report of the upper border of the. Espghan- naspghan guidelines for diagnosis, detection of white blood cell casts suggest atn; reddish-brown urine and emphasize compliance to increase the numbers of support person. 3. Bone marrow is hyperplastic, with a dramatic reduction of symptoms, history of exposure to use coping ...
The primary purpose of this study is to determine if the administration of a higher dose would decrease the chance of tumor recurrence, compared to the risk of tumor recurrence with a lower dose. Most of the treatment will be given protons, but participants may receive a small portion of treatment with x-rays, because less radiation is given to the skin with x-rays. This study uses two slightly different doses of radiation It is not clear at this time which of the dose levels is better ...
The primary purpose of this study is to determine if the administration of a higher dose would decrease the chance of tumor recurrence, compared to the risk of tumor recurrence with a lower dose. Most of the treatment will be given protons, but participants may receive a small portion of treatment with x-rays, because less radiation is given to the skin with x-rays. This study uses two slightly different doses of radiation It is not clear at this time which of the dose levels is better ...
CAMMC of the larynx are rare tumors but have a better prognosis than their axial counterparts (mean, 6 mo). Initial voice-sparing surgery can be followed with more aggressive surgery if recurrences develop.
Alvin Deguzman, long-time bassist of The Icarus Line, has died. He had been battling a rare form of cancer (mesenchymal chondrosarcoma), and finally lost the fight a few hours ago. As someone who has met him several times over the years, I am genuinely saddened by his passing. He was a cool dude. May you […]. ...
In most cases, an x-ray examination is sufficient to determine the diagnosis, but not always.. Biopsy : taking a sample of bone tissue for morphological examination. It is considered the most reliable method of investigation. The procedure is quite painful, and some veterinarians refuse to perform a biopsy with obvious signs of a bone tumor obtained by radiography. With a controversial interpretation of the results of the examination, a biopsy allows you to make a final diagnosis.. Sometimes, around the tumor develops a significant inflammatory process and requires several samples of pathological tissue. Taking samples is not dangerous and does not lead to the formation of a pathological fracture.. Also check out Osteosarcoma causes and symptoms on credihealth.. If this is not an osteosarcoma?. Localization and the results of X-ray examination in osteosarcoma are quite classical, but it is necessary to take into account some possible causes of bone tissue lysis: chondrosarcoma, squamous cell ...
Detailed information on bone cancers, including chondrosarcoma, ewings sarcoma, myeloma bone disease, multiple myeloma, and osteosarcoma
One of the more confusing times in an oncology examination room is describing what a round cell tumor is to a pet owner. The term is broad and describes myriad tumors that appear cytologically or histologically as a monotonous population of undifferentiated cells with high nuclear to cytoplasmic ratios. In dogs, this group includes mesenchymal and epithelial tumors as osteosarcoma, rhabdomyosarcoma, certain melanomas, chondrosarcoma, and basal cell tumors. However, the ultimate …
Provide safer, effective primary and secondary peripheral nerve repair and reconstruction with the GEM Neurotube from Synovis MCA. Its a single-use, absor
The actuarial 5- and 10-year survival rates after GKS were 80 and 53%, respectively. The actuarial 5- and 10-year local tumor control (LTC) rates after single or multiple GKS sessions were 76 and 67%, respectively. All patients with low-grade chondrosarcomas achieved good LTC. A tumor volume of less than 20 ml significantly affected the high rate of LTC (p = 0.0182). No patient had adverse radiation effects, other than one in whom facial numbness worsened despite successful tumor control. ...
Colorectal plasmocytomas are uncommon neoplasias. But when they occur, it is impotant to know how to treat them best: Just wait and see? Do a normal resection or a resection with wide margins which is very difficult in this region? A very informative recently published study.
CT scan and gross pathology of a chondrosarcoma 2012-12-18 "Chondrosarcoma". The Lecturio Medical Concept Library. Retrieved 8 ... A chondrosarcoma is a member of a category of tumors of bone and soft tissue known as sarcomas. About 30% of bone sarcomas are ... Nearly all chondrosarcoma patients appear to be in good health. Often, patients are not aware of the growing tumor until there ... Chondrosarcoma is a bone sarcoma, a primary cancer composed of cells derived from transformed cells that produce cartilage. ...
... is a type of chondrosarcoma. It has been associated with a t(9;22) (q22;q12) EWS/CHN gene fusion. Goh YW ... November 2001). "Extraskeletal myxoid chondrosarcoma: a light microscopic, immunohistochemical, ultrastructural and immuno- ... "Molecular analysis of the fusion of EWS to an orphan nuclear receptor gene in extraskeletal myxoid chondrosarcoma". Am. J. ...
... (EMC) is a rare low-grade malignant mesenchymal neoplasm of the soft tissues, that differs ... "Myxoid Chondrosarcoma - an overview , ScienceDirect Topics". www.sciencedirect.com. Retrieved 2019-02-04. "TAF15 TATA-box ... when they discussed the different species of extraskeletal chondrosarcoma, but EMC concept was firstly proposed in 1972 by ... Yang, Lei; Qin, Genggeng; Xu, Rong; Wang, Ruoning; Zhang, Ling (2018). "Extraskeletal Myxoid Chondrosarcoma: A Comparative ...
"Chondrosarcoma". The Lecturio Medical Concept Library. Retrieved 8 July 2021. "Synovial Chondromatosis". Genetic And Rare ... Synovial chondrosarcoma Other: Osteochondritis dissecans Sequestrum from osteomyelitis Neuropathic (Charcot) joint Intra- ... Malignant transformation to synovial chondrosarcoma. This is a very rare complication occurring in chronic cases. Treatment ...
Chondrosarcoma is a more malignant type of tumor, but most are low grade tumors and often appear in the axial skeletal region. ... S2CID 44703653.[permanent dead link] Aufderheide, A.C.; Rodríguez-Martín, C.; Langsjoen, O. (2011). "Chondrosarcoma". The ...
Depending on the type of chondrosarcoma, it ranges from a slow growth which is able to be removed, to a rapid growth and ... "Chondrosarcoma - Symptoms and causes". Mayo Clinic. Retrieved 2020-04-23. Reference, Genetics Home. "Chordoma". Genetics Home ... There are multiple other bone cancers that are more rare: Chondrosarcoma is identified mainly through the production of ...
... related to chondrosarcoma; CA11, related to stomach cancer; and surfactant protein C (SP-C), related to respiratory distress ...
Coltrera MD, Googe PB, Harrist TJ, Hyams VJ, Schiller AL, Goodman ML (1986). "Chondrosarcoma of the temporal bone. Diagnosis ...
"Chordoma and chondrosarcoma gene profile: implications for immunotherapy". Cancer Immunology, Immunotherapy. 58 (3): 339-49. ... Chondroid chordomas histologically show features of both chordoma and chondrosarcoma. In most cases, complete surgical ...
A person with HME has an increased risk of developing a rare form of bone cancer called chondrosarcoma as an adult. Problems ... Kivioja A, Ervasti H, Kinnunen J, Kaitila I, Wolf M, Böhling T (March 2000). "Chondrosarcoma in a family with multiple ...
" "Chondrosarcoma Masquerading as Cardiomyopathy" ; Charles R. Mulligan, Jr, Houman Tavaf-Motamen, Robert Stewart, and William ...
The benign tumors are called chondroma, the malignant ones chondrosarcoma. Tumors arising from other tissues may also produce a ...
However, the gene has been found to be highly expressed in chondrosarcoma. Chondrosarcoma is the cancer of the cells that ... Therefore, there seems to be an association between IFFO1's filamentous characteristic and chondrosarcoma. One nuclear export ...
Michael Turner, 37, American comic book artist and publisher, chondrosarcoma. Irina Baronova, 89, Russian ballerina, last of ...
Kukreti died from a rare form of cancer, undifferentiated chondrosarcoma. "USA Cricket: Former USA wicketkeeper Rahul Kukreti ...
ISBN 978-0-323-52479-7. Wang XL, De Beuckeleer LH, De Schepper AM, Van Marck E (2001). "Low-grade chondrosarcoma vs enchondroma ... When differentiating an enchondroma from a chondrosarcoma, the radiographic image may be equivocal; however, periostitis is not ...
Drummer Randy Miller died from chondrosarcoma on November 5, 2010. The family set up a place for people to donate money to his ...
B16F10 and chondrosarcoma". Life Sciences. 40 (16): 1601-1607. doi:10.1016/0024-3205(87)90126-3. PMID 3561167. Fryklund, Linda ...
... is implicated in a number of different cancers such as osteosarcomas, chondrosarcomas, bladder cancer, and ... "The clinical significance of tenascin-C splice variant expression in chondrosarcoma". Oncology. 61 (4): 306-14. doi:10.1159/ ...
B16F10 and chondrosarcoma". Life Sciences. 40 (16): 1601-7. doi:10.1016/0024-3205(87)90126-3. PMID 3561167. Fryklund, Linda; ...
"Specific loss of chondromodulin-I gene expression in chondrosarcoma and the suppression of tumor angiogenesis and growth by its ... "Expression of the chondromodulin-I gene in chondrosarcomas". Cancer Letters. 204 (1): 61-8. doi:10.1016/j.canlet.2003.09.015. ...
Fibrosarcoma is the most common VAS; other types include rhabdomyosarcoma, myxosarcoma, chondrosarcoma, malignant fibrous ...
Osteosarcoma, chondrosarcoma arise in bone and cartilage, lymphoma in haematological disorders (1). The most common ...
Failure to stop growth can be indicative of transformation to malignant chondrosarcoma. Treatment is not indicated unless ...
These conditions include chondrosarcoma, osteosarcoma, giant cell tumor, and aneurysmal bone cyst. The temporomandibular joints ...
Abnormalities of chromosome 13 have been observed in canine osteoid chondrosarcoma and lymphosarcoma. Trisomy 13 in dogs with ...
C. Park, A. Husain "PET scan negative metastatic chondrosarcoma," American College of Physicians. Research Presentation. ...
Bone-originating primary tumors such as osteosarcoma, chondrosarcoma, and Ewing's sarcoma are rare; the most common bone tumor ...
These disease states include chondrosarcoma, glioma, kidney tumors, liver tumors, and germ cell tumors. VXN is only expressed ...
Less frequently, it results from some malignant tumors, such as osteosarcoma, chondrosarcoma, and hemangioendothelioma.[ ...
Phase 2 study of INBRX-109 in unresectable or metastatic conventional chondrosarcoma patients. INBRX-109 is a recombinant ... Have conventional chondrosarcoma that is unresectable (=inoperable) or metastatic.. *Have radiologic progression of disease per ... A Randomized, Blinded, Placebo-controlled, Phase 2 Study of INBRX-109 in Unresectable or Metastatic Conventional Chondrosarcoma ... Phase 2 study of INBRX-109 in unresectable or metastatic conventional chondrosarcoma patients. INBRX-109 is a recombinant ...
If you or a loved one has been impacted by skeletal chondrosarcoma cancer, we encourage you to share your story. Help us raise ... The tumor was then diagnosed as an extra skeletal chondrosarcoma. Dr. Morris set a surgery date one week after the biopsy ... Tags: cure sarcomacuresarcomaExtra Skeletal Chondrosarcomasarcomasarcoma cancersarcoma foundation of americaSarcoma Patient ...
Chondrosarcoma is a cartilaginous cancer (a cartilage-based bone cancer) that represents approximately 25% of all primary bone ... In many chondrosarcoma cases, the tissue can be extracted with a needle, but if the chondrosarcoma is located centrally in the ... Chondrosarcoma Symptoms and Features. The symptoms of chondrosarcoma vary depending on the location of the tumor. Furthermore, ... Chondrosarcoma Treatment. Chondrosarcomas are relatively rare. As a result, they are treated at hospitals with specialized ...
Extraskeletal myxoid chondrosarcoma. Long-term experience with chemotherapy.. Am J Clin Oncol. 1995; 18: 161-163. View in ... Activity of sunitinib in extraskeletal myxoid chondrosarcoma.. Eur J Cancer. 2014; 50: 1657-1664. View in Article *Scopus (50) ... Extraskeletal myxoid chondrosarcoma.. in: Fletcher CD Bridge JA Hogendoorn PCW Mertens F WHO classification of tumours of soft ... Anthracycline-based chemotherapy in extraskeletal myxoid chondrosarcoma: a retrospective study.. Clin Sarcoma Res. 2013; 3: 16 ...
I am currently being treated for this rare cancer at Mayo Rochester. Anyone else with this condition? - Page 3
High TIL, HLA, and Immune Checkpoint Expression in Conventional High-Grade and Dedifferentiated Chondrosarcoma and Poor ...
Case of pathologically proven extraskeletal chondrosarcoma. Case courtesy of Dr. George Matcuk. ... Skalski M, Extraskeletal chondrosarcoma. Case study, Radiopaedia.org (Accessed on 06 Dec 2022) https://doi.org/10.53347/rID- ...
... until he learned he had a chondrosarcoma. ... Patient With Chondrosarcoma Feels Confident With His Cancer ... until he learned he had a chondrosarcoma. ...
Chondrosarcomas are mostly seen in the long bones (45%) such as the femur (20-35%), tibia (5%) and proximal humerus (10-20%), ... 3] Pring ME, Weber KL, Unni KK, Sim FH (2001). Chondrosarcoma of the pelvis. A review of sixty-four cases. J Bone Joint Surg Am ... Chondrosarcomas are malignant cartilaginous tumours accounting for about 25% of all primary malignant bone tumours. They can be ... Chondrosarcomas are either primary or secondary arising from a pre-existent cartilaginous lesion such as osteochondroma (aka ...
Novel Prognostication of Patients with Spinal and Pelvic Chondrosarcoma Using Deep Survival Neural Networks:An analysis of the ... Learning Objectives: RED_SNN is a valid method of predicting survival for spinal chondrosarcoma ... including chondrosarcoma. Machine learning (ML) techniques to predict disease have shown higher diagnostic accuracy than ... network ML algorithms for the role and outcomes of surgical resection and radiation therapy in spinal and pelvic chondrosarcoma ...
Chondrosarcoma with Multimodal Therapy Condition and Symptoms. Chondrosarcoma is a type of cancer that involves the cells that ... Treatment for chondrosarcoma may vary depending on where the cancer originated and what stage the cancer is in. Because this ... Chondrosarcoma with Multimodal Therapy and Your Social Security Disability Case. When applying for disability benefits based on ... When an individual is suffering from chondrosarcoma he or she must not only face the symptoms of the cancer itself, but must ...
Dive into the research topics of Interleukin-1β and cyclic AMP mediate the invasion of sheared chondrosarcoma cells via a ... Activated PI3-K and ERK1/2 signaling pathways phosphorylate c-Jun, which in turn transactivates MMP-1 in human chondrosarcoma ... Activated PI3-K and ERK1/2 signaling pathways phosphorylate c-Jun, which in turn transactivates MMP-1 in human chondrosarcoma ... Activated PI3-K and ERK1/2 signaling pathways phosphorylate c-Jun, which in turn transactivates MMP-1 in human chondrosarcoma ...
Connect people with Mesenchymal Chondrosarcoma close to you and help each other. , Diseasemaps ...
Chondrosarcoma of bone with dedifferentiation: A study of eighteen cases. Human pathology. 1982 Jan;13(1):36-40. doi: 10.1016/ ... Chondrosarcoma of bone with dedifferentiation : A study of eighteen cases. / McCarthy, Edward F.; Dorfman, Howard D. ... McCarthy, Edward F. ; Dorfman, Howard D. / Chondrosarcoma of bone with dedifferentiation : A study of eighteen cases. In: Human ... McCarthy, E. F., & Dorfman, H. D. (1982). Chondrosarcoma of bone with dedifferentiation: A study of eighteen cases. Human ...
Chondrosarcoma. NCCN recommendations for treatment of chondrosarcoma are as follows [1] :. * Enrollment in a clinical trial ... and low-grade peripheral chondrosarcomas be surgically excised. Higher-grade chondrosarcomas and all chondrosarcomas of the ... Dedifferentiated chondrosarcoma is often treated as a high-grade bone sarcoma, with systemic and local therapies that need to ... Skull base chondrosarcomas can be treated with high-dose radiation therapy, including proton or carbon ion beam radiation ...
Extra-skeletal chondrosarcoma. Indian Journal of Pathology & Microbiology. 1988 Jan; 31(1): 96-9. ...
Chondrosarcoma is a cancer composed of cells derived from transformed cells that produce cartilage ... Learn and reinforce your understanding of Chondrosarcoma. Check out our video library. ...
Videos for cancer patients made by cancer patients. Views and experiences that the doctors cant tell you.
Posts about bone cancer-chondrosarcoma written by marialeila ... Tag Archives: bone cancer-chondrosarcoma. Waltzing Through The ... Posted in chondrosarcoma, XYZ , Tagged bone cancer-chondrosarcoma, chondrosarcoma, chondrosarcoma grade 1, chondrosarcoma story ... Posted in chondrosarcoma, XYZ , Tagged bone cancer-chondrosarcoma, chondrosarcoma, chondrosarcoma grade 1, chondrosarcoma story ...
Chondrosarcoma in Cats Home » Pet Health » Pet Health Library » Library. What is chondrosarcoma?. Chondrosarcomas arise from ... How does chondrosarcoma typically progress?. Although the mass may grow rapidly, less than 20% of chondrosarcoma cases in cats ... Cats with chondrosarcoma of the long bones often develop lameness as the first clinical sign of chondrosarcoma. This lameness ... What are the treatments for chondrosarcoma?. Surgical excision is the treatment of choice for chondrosarcoma, if feasible. This ...
Chondrosarcoma of bone: an assessment of outcome. F Y Lee, H J Mankin, G Fondren, M C Gebhardt, D S Springfield, A E Rosenberg ... Dedifferentiated chondrosarcoma. A study of 13 clinical cases and review of the literature]. P Anract, B Tomeno, M Forest Revue ... Pelvic chondrosarcomas: surgical treatment options. X Deloin, V Dumaine, D Biau, M Karoubi, A Babinet, B Tomeno, P Anract ... Dedifferentiated chondrosarcoma: the role of chemotherapy with updated outcomes. Ian D Dickey, Peter S Rose, Bruno Fuchs, ...
Dedifferentiated Chondrosarcoma is a cancer for which foods and supplements recommended and those to avoid must be personalized ... Tags: Dedifferentiated Chondrosarcoma , Dedifferentiated Chondrosarcoma chemotherapy , Dedifferentiated Chondrosarcoma genetic ... Dedifferentiated Chondrosarcoma treatment , diet Dedifferentiated Chondrosarcoma , foods for Dedifferentiated Chondrosarcoma , ... 2. Significance of Nutrition for Dedifferentiated Chondrosarcoma 3. Foods for Dedifferentiated Chondrosarcoma undergoing ...
18 thoughts on "Chondrosarcoma: Background and current status" * Tammy Crutsinger says: So sorry to hear this ! You and your ... Both masses came back positive as Chondrosarcoma so 2 weeks later I had surgery on my left lung. Again, not a fun recovery but ... Chondrosarcoma: Background and current status. December 20, 2015. December 20, 2015. cgb21 ... We were hoping that I would be eligible for a trial that has had some success in Chondrosarcoma but unfortunately, my cancer ...
5: Malignant tumors: Chordomas and chondrosarcomas. *6: Malignant tumors: Solitary fibrous tumor/hemangiopericytoma ...
Chondrosarcomas are the most common malignant tumors of the cartilage, are seen predominantly in adults, and have varied ... Non-Conventional Treatments for Conventional Chondrosarcoma Authors: Varun Monga, Hariharasudan Mani, Angela Hirbe, Mohammed ... Chondrosarcomas are the most common malignant tumors of the cartilage, are seen predominantly in adults, and have varied ... The prognosis of chondrosarcoma is closely related to histological grading; however, the grading is subject to interobserver ...
Chondrosarcoma (Chs) is the third most frequent primary malignant tumour of bone and can be primary or secondary, the latter ... Chondrosarcoma (Chs) is the third most frequent primary malignant tumour of bone and can be primary or secondary, the latter ... Therefore, the aims of this study are firstly the analysis of heterogeneity in Chondrosarcomas by means of TMA technology using ... Bovee JV, Cleton-Jansen AM, Taminiau AH, Hogendoorn PC: Emerging pathways in the development of chondrosarcoma of bone and ...
Comprehensive information about Clear Cell Chondrosarcoma including signs and symptoms, diagnosis, radiology, pathology, ... chondrosarcoma, clear cell chondrosarcoma, diagnosis clear cell chondrosarcoma, radiology clear cell chondrosarcoma, pathology ... clear cell chondrosarcoma, surgery clear cell chondrosarcoma, prognosis clear cell chondrosarcoma, epiphyseal tumor, cartilage ... Thank-you so very much for being my surgeon for that chondrosarcoma, for saving my life! And I have learned over the months ( ...
  • The tumor was then diagnosed as an extra skeletal chondrosarcoma. (curesarcoma.org)
  • The symptoms of chondrosarcoma vary depending on the location of the tumor. (knowcancer.com)
  • Chondrosarcoma is a rare tumor in cats, but it can occur. (applecrossvet.ca)
  • The clinical signs of chondrosarcoma may vary significantly, depending upon where the tumor arises. (applecrossvet.ca)
  • Clinical signs associated with chondrosarcoma at these sites will vary depending on the location of the tumor. (applecrossvet.ca)
  • Dedifferentiated chondrosarcoma is a rare, highly malignant tumor with a poor survival. (qxmd.com)
  • These tumor genetic details of Dedifferentiated Chondrosarcoma are mapped to molecular biochemical pathway drivers of cancer thereby providing definition of characteristic features of Dedifferentiated Chondrosarcoma. (addon.life)
  • The symptoms of Chondrosarcoma may vary widely according to the location of the affected cells and tumor. (csfshayna.org)
  • We present a case of dedifferentiated chondrosarcoma with rhabdomyosarcomatous differentiation harboring a prominent rhabdoid tumor component. (bvsalud.org)
  • Typical considerations for this end-of-bone neoplastic lesion are giant cell tumor, clear cell chondrosarcoma, and chondroblastoma. (elsevier.com)
  • To develop a machine learning model based on 3D MRI radiomics to differentiate atypical cartilaginous tumor (ACT) from grade II chondrosarcoma (CS2) of long bones. (convegnonazionaleaiic.it)
  • Chondrosarcoma is a malignant tumor that is characterized by the formation of cartilage by tumor. (gopetsamerica.com)
  • Although dedifferentiation in a chondrosarcoma was strongly considered, the pattern was considered unusual and the possibility of a collision tumor (enchondroma with desmoplastic fibroma) was also entertained, with recommended treatment to achieve control of a locally aggressive neoplasm. (biomedscis.com)
  • Chondrosarcoma is a malignant tumor occupying the 2nd position in terms of frequency, all ages combined, after osteosarcoma [1]. (peertechzpublications.com)
  • Chondrosarcoma, a malignant tumor of cartilaginous origin, is the most common of the adult primary bone cancers. (drrathresearch.org)
  • Chondrosarcoma (CS), a malignancy of cartilaginous origin, is an aggressive cancer with poor prognosis, due to both its aggressive metastatic spread and the lack of efficacy in current treatment modalities to prevent or counteract tumor progression. (drrathresearch.org)
  • In the latest version of the guidelines released in November 2020, surgery is the main treatment for chondrosarcoma, chordoma, and giant cell tumor of bone, which can be combined with radiotherapy or targeted therapy. (bvsalud.org)
  • With patients who present with locally advanced or metastatic chondrosarcoma, chordoma, or osteosarcoma, physicians should discuss the options surrounding deep-sequencing genomic tests, which may identify mutations that may be responsive to specific therapies and thus may guide referral to clinical trials. (medscape.com)
  • Surgical en bloc resection with negative margins is the only curative treatment for chordoma. (medscape.com)
  • Chondrosarcoma (Chs) is the third most frequent primary malignant tumour of bone exceeded only by myeloma and osteosarcoma. (biomedcentral.com)
  • He has managed many complex cases in both adults and children, including osteosarcoma, chondrosarcoma, and Ewing's sarcoma. (doctify.com)
  • Fourteen histopathologic types were found of which osteosarcoma (28%), chondrosarcoma (17%), rhabdomyosarcoma (12%) and fibrosarcoma (12%) were predominant. (bvsalud.org)
  • The Surveillance, Epidemiology, and End Results (SEER) database has been queried to include all malignant osseous spinal tumors, including chondrosarcoma. (cns.org)
  • Chondrosarcomas are the most common malignant tumors of the cartilage, are seen predominantly in adults, and have varied clinical behavior. (internalmedicineiowa.org)
  • Dedifferentiated chondrosarcomas (DDCS) are rare lesions, defined as tumors having a low-grade chondrosarcomatous component with an abrupt transition to a high-grade sarcoma . (bvsalud.org)
  • Mesenchymal chondrosarcomas (MCs) are infrequent, slowâ growing malignant tumors of head and neck region affecting both bone and soft tissues. (amhsr.org)
  • Chondrosarcomas are tumors composed of cancerous cartilage cells. (msdmanuals.com)
  • Many chondrosarcomas are slow-growing or low-grade tumors, meaning that they are less likely to spread (metastasize) than some other tumors. (msdmanuals.com)
  • However, some chondrosarcomas are fast-growing or high-grade tumors, which tend to metastasize. (msdmanuals.com)
  • We sought to develop and validate deep survival neural network ML algorithms to predict survival following diagnosis of chondrosarcoma, using a SEER database. (cns.org)
  • When you file a Social Security Disability claim based on a diagnosis of chondrosarcoma and you are undergoing multimodal therapy to treat the condition, you will need to provide very detailed answers to the SSA regarding the affect the condition has had on your daily lifestyle. (disabilitybenefitscenter.org)
  • Final diagnosis was based on histological examination, which confirmed the hypothesis of low-grade parafalcine chondrosarcoma. (neoplasiaresearch.com)
  • According to the American Cancer Society, Chondrosarcomas develops most often in adults, with an average age at diagnosis of 51 . (jeffersoncityheadlines.com)
  • Activated PI3-K and ERK1/2 signaling pathways phosphorylate c-Jun, which in turn transactivates MMP-1 in human chondrosarcoma cells. (elsevier.com)
  • Collectively, fluid shear stress upregulates matrix MMP-1 expression, which is responsible for the enhanced invasion of human chondrosarcoma cells. (elsevier.com)
  • Dive into the research topics of 'Cell density-dependent proliferative effects of transforming growth factor (TGF)-β1, β2, and β3 in human chondrosarcoma cells HCS-2/8 are associated with changes in the expression of TGF-β receptor type I'. Together they form a unique fingerprint. (elsevier.com)
  • McCarthy, EF & Dorfman, HD 1982, ' Chondrosarcoma of bone with dedifferentiation: A study of eighteen cases ', Human pathology , vol. 13, no. 1, pp. 36-40. (elsevier.com)
  • Twenty-three patients with dedifferentiated chondrosarcoma confirmed by pathology were retrospectively reviewed from 2008 to 2015. (qxmd.com)
  • Because the combination of symptoms can leave a person completely disabled, a case of chondrosarcoma with multimodal therapy may qualify an individual for claim processing under the SSA's Compassionate Allowances guidelines. (disabilitybenefitscenter.org)
  • In the case of chondrosarcoma with multimodal therapy, this will include lab results, imaging results, treatment histories and written statements from your treating physician. (disabilitybenefitscenter.org)
  • When applying for disability benefits based on a case of chondrosarcoma with multimodal therapy you may want to enlist the assistance of an attorney who specializes in disability cases. (disabilitybenefitscenter.org)
  • In the case of chondrosarcoma, no specific risk factors or cause have been identified. (applecrossvet.ca)
  • Based on the poor prognosis of chondrosarcoma, we investigated effects of a phytonutrient mixture (PB) containing quercetin, CruciferexTM, curcumin, resveratrol and green tea extract on several parameters associated with the development of this type of cancer. (drrathresearch.org)
  • Nearly 30 percent of cancers that affect the skeletal system are classified as chondrosarcomas. (disabilitybenefitscenter.org)
  • For cancers like Dedifferentiated Chondrosarcoma when undergoing chemotherapy or when you determine you have a genetic risk for developing Dedifferentiated Chondrosarcoma because of IDH1 and POLE gene mutations, a very important question is "What foods should I avoid and what foods are recommended specifically for me? (addon.life)
  • There is no one answer to this question for cancers such as Dedifferentiated Chondrosarcoma which can be found through internet searches. (addon.life)
  • Forty percent of primary bone cancers are chondrosarcoma. (drrathresearch.org)
  • Coexistence of Extraskeletal Mesenchymal Chondrosarcoma and Isolated Hemihyperplasia: A Case Report. (docksci.com)
  • Coex stence of Extraskeletal Mesenchymal Chondrosarcoma and Isolated Hem hyperplas a: A Case Report Nihat Demirhan Demirkiran¹, Olcay Akdeniz¹, Onur Hapa¹, Hasan Havıtçıoğlu¹ What to Learn from this Article? (docksci.com)
  • Parker JR, Zarabi MC, Parker JC Jr. Intracerebral mesenchymal chondrosarcoma. (neoplasiaresearch.com)
  • Dedifferentiated chondrosarcoma: the role of chemotherapy with updated outcomes. (qxmd.com)
  • Conventional chondrosarcomas are overall considered to be chemotherapy- and radiation-resistant, resulting in limited treatment options. (internalmedicineiowa.org)
  • The majority of advanced conventional chondrosarcomas are treated with chemotherapy without any survival benefit. (internalmedicineiowa.org)
  • However as chondrosarcoma typically does not respond to radiation and chemotherapy, surgery is the main treatment option. (drrathresearch.org)
  • This corresponded to combined histologic patterns of high grade sarcoma, usually with features of a malignant fibrous histiocytoma, and a low grade chondrosarcoma. (elsevier.com)
  • Dedifferentiation of a low-grade chondrosarcoma is thought to occur when a high-grade sarcoma develops within the locally aggressive lesion [1]. (biomedscis.com)
  • Skalski M, Extraskeletal chondrosarcoma. (radiopaedia.org)
  • Case of pathologically proven extraskeletal chondrosarcoma . (radiopaedia.org)
  • A rare type of chondrosarcoma called extraskeletal chondrosarcoma does not form in bone cartilage. (cancer.gov)
  • abstract = "Matrix metalloproteinase-1 (MMP-1) is a potential biomarker for chondrosarcoma that is overexpressed at the invading edges of articular cartilage, and its expression correlates with poor survival rates. (elsevier.com)
  • This study presents an analysis (efficacy and toxicity) of outcomes in patients with skull-base chordomas or chondrosarcomas treated with a fixed horizontal pencil proton beam. (biomedcentral.com)
  • Chordomas (CAs) and chondrosarcomas (CSAs) are rare tumours that are usually located near the base of the skull and very close to the brain's most critical structures. (biomedcentral.com)
  • Treatment with a fixed proton beam shows promising disease control and an acceptable toxicity rate, even the difficult-to-treat subpopulation of patients with skull-base chordomas or chondrosarcomas requiring dose escalation. (biomedcentral.com)
  • Chordomas and chondrosarcomas are rare among malignancies and mainly affect the skull base, sacrum bones, and vertebral column (less). (biomedcentral.com)
  • Chondroid describes chordomas that are difficult to distinguish from chondrosarcoma on histology. (medscape.com)
  • Typically, chordomas express the brachyury gene, whereas chondrosarcomas do not express this gene. (medscape.com)
  • This study is the first to analyze population-level data using artificial neural network ML algorithms for the role and outcomes of surgical resection and radiation therapy in spinal and pelvic chondrosarcoma. (cns.org)
  • Pelvic chondrosarcomas: surgical treatment options. (qxmd.com)
  • Imaging is important to differentiate benign osteochondromas from chondrosarcomas and to identify hereditary multiple exostoses syndrome, who is more likely to become malignant. (eurorad.org)
  • Dedifferentiated chondrosarcomas arising in preexisting osteochondromas. (qxmd.com)
  • 2019), most Chondrosarcomas are sporadic, but they may develop from the malignant transformation of osteochondromas and enchondromas. (jeffersoncityheadlines.com)
  • Have conventional chondrosarcoma that is unresectable (=inoperable) or metastatic. (rush.edu)
  • In this review article, we explore ongoing clinical trials evaluating novel ways of treating advanced conventional chondrosarcoma. (internalmedicineiowa.org)
  • A 78-year-old female patient with a lesion in the distal tibia is shown to have conventional intramedullary chondrosarcoma. (elsevier.com)
  • Salient clinical and radiographic features and behavior of this lesion broaden the typical view of conventional intramedullary chondrosarcoma. (elsevier.com)
  • Kothary N, Law M, Cha S, Zagzag D. Conventional and Perfusion MR Imaging of Parafalcine Chondrosarcoma. (neoplasiaresearch.com)
  • Chondrosarcoma is a cartilaginous cancer (a cartilage-based bone cancer) that represents approximately 25% of all primary bone cancer cases. (knowcancer.com)
  • Chondrosarcomas are malignant cartilaginous tumours accounting for about 25% of all primary malignant bone tumours. (eurorad.org)
  • Chondrosarcoma begins in cartilaginous tissue. (cancer.gov)
  • Dedifferentiated chondrosarcoma typically has 2 microscopic components, whereby the low-grade cartilaginous lesion is seen with a high grade sarcomatous component with an abrupt transition between the 2 zones [1]. (biomedscis.com)
  • The procedure was performed under image intensifier control and the histological picture of the specimen showed features of a dedifferentiated lowgrade chondrosarcoma with abrupt demarcation between a distinct cartilaginous component and a spindle cell component. (biomedscis.com)
  • Most chondrosarcomas arise de novo, but some may develop in a preexisting benign cartilaginous lesion or in patients with ENCHONDROMATOSIS . (bvsalud.org)
  • Initial screening tests for chondrosarcoma typically involves screening laboratory tests (bloodwork and urinalysis), as well as radiographs (X-rays) of the affected bone or joint. (applecrossvet.ca)
  • How does chondrosarcoma typically progress? (applecrossvet.ca)
  • Chondrosarcoma is a cartilage forming tumour, typically found in flat bones such as the ilium. (biomedscis.com)
  • Chondrosarcomas arise from cartilage, which is a connective tissue found where bones meet with joints. (applecrossvet.ca)
  • Approximately 44% of cases of chondrosarcoma in cats are found in the long bones, which are the bones that are found in the legs. (applecrossvet.ca)
  • Cats with chondrosarcoma of the long bones often develop lameness as the first clinical sign of chondrosarcoma. (applecrossvet.ca)
  • What are the clinical signs of chondrosarcoma? (applecrossvet.ca)
  • Clinical outcome for patients with dedifferentiated chondrosarcoma: a report of 9 cases at a single institute. (qxmd.com)
  • Following key highlights are derived from clinical data for Dedifferentiated Chondrosarcoma from cBioPortal. (addon.life)
  • Currently, Inhibrx has its Chondrosarcoma drug candidates in the most advanced stage of clinical development. (jeffersoncityheadlines.com)
  • Chondrosarcoma is a rare form of bone cancer that develops in cartilage cells, particularly that of the femur, arm, pelvis, knee, and ribs. (csfshayna.org)
  • Chondrosarcoma is a bone sarcoma that develops in the cartilage cells. (jeffersoncityheadlines.com)
  • Surgical resection is considered to be the standard method, and only curative method, for treating chondrosarcoma. (knowcancer.com)
  • Surgical excision is the treatment of choice for chondrosarcoma, if feasible. (applecrossvet.ca)
  • Overall 5-year survival is approximately 50%, and treatment consists of en bloc surgical resection followed by high-dose conformal radiation therapy (RT) such as proton beam radiation. (medscape.com)
  • Chondrosarcoma most often forms in the pelvis , upper leg, and shoulder and usually grows slowly, although sometimes it can grow quickly and spread to other parts of the body. (cancer.gov)
  • Neoplasia maligna derivada de células cartilaginosas, más frecuente en los huesos de la pelvis o cerca de los extremos de los huesos largos, en personas maduras y ancianas. (bvsalud.org)
  • When an individual is suffering from chondrosarcoma he or she must not only face the symptoms of the cancer itself, but must also deal with the symptoms associated with the treatments that are being administered. (disabilitybenefitscenter.org)
  • Treatment for chondrosarcoma may vary depending on where the cancer originated and what stage the cancer is in. (disabilitybenefitscenter.org)
  • Treatment strategies for Chondrosarcoma rely on the removal of the tumorous mass and reducing the likelihood it will return. (csfshayna.org)
  • Even though surgery remains the mainstay of treatment for cerebral chondrosarcomas, adjuvant radiotherapy such as stereotactic, proton beam or carbon ion-beam therapy might be necessary in aggressive or incomplete removed cases. (neoplasiaresearch.com)
  • The Chondrosarcoma Foundation, Inc. will host their fourth International Forum / Virtual Dialogue featuring the following prominent experts to address new innovations, findings and technologies to improve the treatment of Chondrosarcoma. (csfshayna.org)
  • The Chondrosarcoma market report covers emerging drugs, current treatment practices, market share of the individual therapies, and current & forecasted market size from 2019 to 2032. (jeffersoncityheadlines.com)
  • In many chondrosarcoma cases, the tissue can be extracted with a needle, but if the chondrosarcoma is located centrally in the body, then the biopsy necessitates surgery. (knowcancer.com)
  • Potential sampling error in fine needle aspiration biopsy of dedifferentiated chondrosarcoma: a report of 4 cases. (qxmd.com)
  • New cortical irregularity or continued growth after skeletal maturity, as well as frankly aggressive features (e.g. bony destruction, large soft tissue component, metastases) are all worrying for malignant transformation to chondrosarcoma. (eurorad.org)
  • While the exact cause of chondrosarcoma is unknown, it is thought that patients who have a history of osteochondroma or enchondroma are at an increased risk of developing this type of cancer. (disabilitybenefitscenter.org)
  • In cases where the chondrosarcoma affects the skull, spine, or chest cavity, a neurosurgeon or a thoracic surgeon usually performs the operation. (knowcancer.com)
  • Chondrosarcomas are known to be the third most common malignant tumour occurring in bone and constitutes approximately 20% of primary bone sarcomas [3]. (biomedscis.com)
  • Chondrosarcoma (Chs) is the third most frequent primary malignant tumour of bone and can be primary or secondary, the latter results mainly from the malignant transformation of a benign pre-existing tumour. (biomedcentral.com)
  • Eighteen patients with chondrosarcomas showing dedifferentiation were reviewed. (elsevier.com)
  • This pattern of dedifferentiation occurs in about 10% of chondrosarcomas [2,3]. (biomedscis.com)
  • What are the treatments for chondrosarcoma? (applecrossvet.ca)
  • The overall objective of personalized nutrition for Dedifferentiated Chondrosarcoma is to minimize foods and nutritional supplements which have adverse interactions with cancer molecular drivers and ongoing treatments. (addon.life)
  • Chondrosarcoma occurs mainly in older adults (over age 40). (cancer.gov)
  • Chondrosarcomas are relatively rare. (knowcancer.com)
  • He stated, "You have been diagnosed with a rare bone cancer called Chondrosarcoma. (cgbblog.net)
  • Chondrosarcoma is a rare malignant tumour arising from the cartilage with a high variability in the clinicalcourse and overall prognosis. (neoplasiaresearch.com)
  • Significant inhibition of important hallmarks of cancer progression by PB mixture suggests that this nutrient composition should be explored further as a therapeutic agent in chondrosarcoma. (drrathresearch.org)
  • Chondrosarcoma is a type of cancer that involves the cells that are created from the transformed cells that produce cartilage. (disabilitybenefitscenter.org)
  • We were hoping that I would be eligible for a trial that has had some success in Chondrosarcoma but unfortunately, my cancer does not have the eligible mutation. (cgbblog.net)
  • According to the US Surveillance, Epidemiology and End Results Program, Chondrosarcomas contribute to 30% of different types of bone cancer. (jeffersoncityheadlines.com)
  • Chondrosarcomas are characterized by high levels of proteases, which are involved in the degradation of ECM and the basement membrane, thus allowing cancer cells to invade and metastasize to distal organs. (drrathresearch.org)
  • Histological features were consistent with a dedifferentiated chondrosarcoma. (biomedscis.com)
  • In addition, patients who suffer from Ollier disease and Maffucci syndrome may also be at an increased risk of developing chondrosarcoma. (disabilitybenefitscenter.org)
  • Nearly 26% of chondrosarcoma cases in cats involve the flat bones. (applecrossvet.ca)
  • Recent studies have evaluated molecular genetic findings which have improved the understanding of chondrosarcoma biology. (internalmedicineiowa.org)
  • There may be a genetic or chromosomal component that makes certain people more likely to develop Chondrosarcoma. (csfshayna.org)
  • Following a complete medical history review and several standard physical exam procedures, a chondrosarcoma may be diagnosed using a variety of imaging techniques. (knowcancer.com)